Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertension and angiogenesis.

F N Kiefer1, S Neysari, R Humar

  • 1Medical Outpatient Department and Department of Research, University Hospital, CH-4031 Basel, Switzerland.

Current Pharmaceutical Design
|July 23, 2003
PubMed
Summary

Arterial hypertension impairs angiogenesis, the formation of new blood vessels, contributing to organ damage. Restoring nitric oxide (NO) and regulating the Renin-Angiotensin-Aldosteron-System (RAAS) may reverse this, aiding treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Brain Metastases on Quality of Life and Estimated Life Expectancy in Patients with Advanced Non-Small Cell Lung Cancer.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action.

International journal of clinical practice·2010
Same author

Angiogenesis and hypertension: an update.

Journal of human hypertension·2009
Same author

RACK1 is up-regulated in angiogenesis and human carcinomas.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2000
Same author

The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation.

Molecular biology of the cell·1999
Same author

The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial.

Journal of cardiovascular pharmacology·1999

Area of Science:

  • Cardiovascular Biology
  • Vascular Biology
  • Hypertension Research

Background:

  • Arterial hypertension (AH) involves reduced nitric oxide (NO) and activated Renin-Angiotensin-Aldosteron-System (RAAS), leading to vasoconstriction and microvascular rarefaction.
  • Microvascular rarefaction in AH contributes to target organ damage, such as left ventricular hypertrophy, potentially due to impaired angiogenesis.
  • Angiogenesis, crucial for relieving ischemia, appears compromised in AH, though blood pressure alone isn't the sole factor.

Purpose of the Study:

  • To investigate the role of nitric oxide (NO) and the Renin-Angiotensin-Aldosteron-System (RAAS) in angiogenesis within the context of arterial hypertension (AH).
  • To explore how factors like Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) interact with NO in angiogenesis.
  • To determine the potential of therapeutic interventions targeting NO biosynthesis and RAAS to improve angiogenesis and mitigate hypertension-associated organ damage.

Related Experiment Videos

Main Methods:

  • Review of existing literature on nitric oxide (NO) pathways, angiogenesis, and the Renin-Angiotensin-Aldosteron-System (RAAS) in hypertension models.
  • Analysis of studies involving endothelial NO synthase (eNOS) knockout mice and other in vivo models of AH.
  • Examination of the effects of angiogenic growth factors (VEGF, FGF) and RAAS components (Bradykinin, Angiotensin II) on NO production and microvascular formation.

Main Results:

  • Reduced NO biosynthesis is linked to impaired angiogenesis in AH models.
  • Normal or elevated NO levels can promote angiogenesis, as seen in other conditions.
  • Angiogenic factors like VEGF and FGF require NO to function, while RAAS components have complex effects on angiogenesis.

Conclusions:

  • Impaired angiogenesis in AH is associated with reduced NO and influenced by the RAAS.
  • Therapeutic strategies aimed at normalizing NO biosynthesis and modulating RAAS activity, such as ACE inhibitors and AT1 receptor antagonists, may restore vascularization.
  • Reversing impaired angiogenesis holds promise for treating hypertension-related target organ damage, including left ventricular hypertrophy.